- The phase-three human clinical test of Covaxin against the novel coronavirus started at the AIIMS in New Delhi.
- Bharat Biotech is designing Covaxin with the Indian Council of Medical Research (ICMR).
THDNewsDesk: On Thursday, the phase-three human clinical test of Covaxin, a vaccine against the novel coronavirus, started at the AIIMS in New Delhi. The clinical trial started as Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other patients got the first dose.
The developed possible anti-coronavirus, Covaxin, is being designed by Bharat Biotech with the Indian Council of Medical Research (ICMR).
Sources stated that Dr Srivastava was the first one to take the first trial dose, which would be provided to approximately 15,000 volunteers in Delhi’s AIIMS Hospital in the next few days.
Srivastava stated, “Covaxin is the first indigenously-developed anti-coronavirus vaccine, and on top of that, my institute is participating in the trial. I am honoured to be the first volunteer to receive the shot. I am happy to be a part of such a great cause. I am excellent, and I’m working for a news agency.”
As per the test proceeds, a dose of 0.5 ml would be provided on day 0 and day 28.
Apart from Covaxin in India, four other possible vaccines are under several stages of a human clinical test with the Serum Institute of India leading a phase-three trial of the Oxford-Astrazeneca Covid-19 vaccine. In contrast, the indigenously advanced vaccine by Zydus Cadila has developed a phase-two clinical trial in the country.